The Fibrinolytic System: from Petri Dishes to Genetic Engineering

That a blood clot dissolves spontaneously was described by Denys in 1889 (1); this phenomenon was termed “fibrinolysis” by Dastre in 1893 (2) and a Belgian countryman, Nolf, demonstrated in 1908 that not only blood coagulation but also fibrinolysis were proteolytic processes (3). The Russian Yudin attracted much attention when he published that cadaver blood can be used for transfusion purposes avoiding coagulation problems (4). He very appropriately selected victims of accidents or sudden death to collect blood to be transfused long before it was known that sudden death is associated with an augmented endogenous fibrinolysis compared to those who die from chronic illness

[1]  H. Lijnen,et al.  Development of novel thrombolytic agents , 1994, Journal of internal medicine.

[2]  D. Collen,et al.  On the Immunogenicity of Recombinant Staphylokinase in Patients and in Animal Models , 1994, Thrombosis and Haemostasis.

[3]  D. Collen,et al.  Staphylokinase, a fibrin-specific plasminogen activator with therapeutic potential? , 1994, Blood.

[4]  W. Schleuning,et al.  Coronary Thrombolysis With Desmodus Salivary Plasminogen Activator in Dogs: Fast and Persistent Recanalization by Intravenous Bolus Administration , 1994, Circulation.

[5]  U. Tebbe,et al.  Dose finding with a novel recombinant plasminogen activator (BM 06.022) in patients with acute myocardial infarction: results of the German Recombinant Plasminogen Activator Study. A study of the Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte (ALKK). , 1994, Journal of the American College of Cardiology.

[6]  B. Schlott,et al.  Functional properties of recombinant staphylokinase variants obtained by site-specific mutagenesis of methionine-26. , 1994, Biochimica et biophysica acta.

[7]  E. Madison.  Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis , 1994 .

[8]  C. Wilson,et al.  Efficacy of 100 mg of double-bolus alteplase in achieving complete perfusion in the treatment of acute myocardial infarction. , 1994, Journal of the American College of Cardiology.

[9]  Gusto Angiographic Investigators.  The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. , 1993, The New England journal of medicine.

[10]  A. Maseri,et al.  Thrombin generation after fast or prolonged regimens of tissue-type plasminogen activator , 1993, The Lancet.

[11]  S. Fischer,et al.  BM 06.022: A Novel Recombinant Plasminogen Activator , 1993 .

[12]  U. Tebbe,et al.  Open, noncontrolled dose-finding study with a novel recombinant plasminogen activator (BM 06.022) given as a double bolus in patients with acute myocardial infarction. , 1993, The American journal of cardiology.

[13]  B. Schlott,et al.  Mechanisms of activation of mammalian plasma fibrinolytic systems with streptokinase and with recombinant staphylokinase. , 1993, European journal of biochemistry.

[14]  F. Van de Werf,et al.  Coronary Thrombolysis With Recombinant Staphylokinase in Patients With Evolving Myocardial Infarction , 1993, Circulation.

[15]  R. Lijnen,et al.  Development of chimeric tissue-type/urokinase-type plasminogen activators for thrombolytic therapy , 1993 .

[16]  D. Collen,et al.  Biochemical-properties of natural and recombinant staphylokinase , 1992 .

[17]  S. Fischer,et al.  Mapping of the catalytic site of CHO‐t‐PA and the t‐PA variant BM 06.022 by synthetic inhibitors and substrates , 1992, Protein science : a publication of the Protein Society.

[18]  B. Sobel,et al.  Questions unresolved by the Third International Study of Infarct Survival. , 1992, The American journal of cardiology.

[19]  U. Tebbe,et al.  Improved thrombolysis in acute myocardial infarction with front-loaded administration of alteplase: results of the rt-PA-APSAC patency study (TAPS) , 1992, Journal of the American College of Cardiology.

[20]  W. Schleuning,et al.  Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. , 1992, Blood.

[21]  J. Lynch,et al.  Vampire bat salivary plasminogen activator promotes rapid and sustained reperfusion without concomitant systemic plasminogen activation in a canine model of arterial thrombosis. , 1992, Arteriosclerosis and thrombosis : a journal of vascular biology.

[22]  K. Strein,et al.  Pharmacokinetics of the Novel Recombinant Plasminogen Activator BM 06.022 in Rats, Dogs, and Non-human Primates , 1992 .

[23]  R. Rudolph,et al.  Biochemical properties of the kringle 2 and protease domains are maintained in the refolded t-PA deletion variant BM 06.022. , 1992, Protein engineering.

[24]  B. Haendler,et al.  The plasminogen activator family from the salivary gland of the vampire bat Desmodus rotundus: cloning and expression. , 1991, Gene.

[25]  L. Nelles,et al.  Thrombolytic and Pharmacokinetic Properties of Chimeric Tissue‐Type and Urokinase‐Type Plasminogen Activators , 1991, Circulation.

[26]  C. Grines,et al.  A Prospective, Randomized Trial Comparing Combination Half‐Dose Tissue‐Type Plasminogen Activator and Streptokinase With Full-Dose Tissue‐Type Plasminogen Activator , 1991 .

[27]  D. Collen,et al.  Strategies for the Improvement of Thrombolytic Agents , 1991, Thrombosis and Haemostasis.

[28]  S. Gardell,et al.  Effective Thrombolysis Without Marked Plasminemia After Bolus Intravenous Administration of Vampire Bat Salivary Plasminogen Activator in Rabbits , 1991, Circulation.

[29]  R. Rudolph,et al.  Thrombolysis with an Escherichia coli-Produced Recombinant Plasminogen Activator (BM 06.022) in the Rabbit Model of Jugular Vein Thrombosis , 1991, Thrombosis and Haemostasis.

[30]  S. Gardell,et al.  Vampire bat salivary plasminogen activator is quiescent in human plasma in the absence of fibrin unlike human tissue plasminogen activator. , 1990, Blood.

[31]  L. Duong,et al.  Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. , 1989, The Journal of biological chemistry.

[32]  A. Corti,et al.  Production and characterisation of human recombinant single chain urokinase-type plasminogen activator from mouse cells , 1989 .

[33]  V. Gurewich,et al.  Activation of plasminogen by single-chain urokinase or by two-chain urokinase--a demonstration that single-chain urokinase has a low catalytic activity (pro-urokinase). , 1987, Blood.

[34]  R. Rajagopalan.  Streptokinase in Acute Myocardial Infarction , 1986, The Lancet.

[35]  H. Heyneker,et al.  Cloning and Expression of the Gene for Pro-urokinase in Escherichia coli , 1985, Bio/Technology.

[36]  B E Sobel,et al.  Coronary thrombolysis with recombinant human tissue-type plasminogen activator: a prospective, randomized, placebo-controlled trial. , 1984, Circulation.

[37]  D. Pennica,et al.  Biological properties of human tissue-type plasminogen activator obtained by expression of recombinant DNA in mammalian cells. , 1984, The Journal of pharmacology and experimental therapeutics.

[38]  J. J. Spadaro,et al.  Coronary thrombolysis with recombinant human tissue-type plasminogen activator. , 1984, Circulation.

[39]  D. Collen,et al.  Biological and Thrombolytic Properties of Proenzyme and Active Forms of Human Urokinase – II. Turnover of Natural and Recombinant Urokinase in Rabbits and Squirrel Monkeys , 1984, Thrombosis and Haemostasis.

[40]  V. Gurewich,et al.  Effective and fibrin-specific clot lysis by a zymogen precursor form of urokinase (pro-urokinase). A study in vitro and in two animal species. , 1984, The Journal of clinical investigation.

[41]  R. W. Scott,et al.  Purification of human fibroblast urokinase proenzyme and analysis of its regulation by proteases and protease nexin. , 1984, Journal of Biological Chemistry.

[42]  B. Sobel,et al.  Coronary thrombolysis with intravenously administered human tissue-type plasminogen activator produced by recombinant DNA technology. , 1984, Circulation.

[43]  D. Collen,et al.  Coronary thrombolysis and infarct sizes reduction following intravenous infusion of recombinant tissue-type plasminogen activator in non-human primates , 1984 .

[44]  M. Ter-pogossian,et al.  Clot-selective coronary thrombolysis with tissue-type plasminogen activator. , 1983, Science.

[45]  J. Zeuthen,et al.  Purification of zymogen to plasminogen activator from human glioblastoma cells by affinity chromatography with monoclonal antibody. , 1982, Biochemistry.

[46]  L. Flohé,et al.  The complete amino acid sequence of low molecular mass urokinase from human urine. , 1982, Hoppe-Seyler's Zeitschrift fur physiologische Chemie.

[47]  W. Schleuning,et al.  Isolation and characterization of urokinase from human plasma. , 1982, The Journal of biological chemistry.

[48]  G. Opdenakker,et al.  Messenger RNA for human tissue plasminogen activator. , 1982, European journal of biochemistry.

[49]  W. Weimar,et al.  SPECIFIC LYSIS OF AN ILIOFEMORAL THROMBUS BY ADMINISTRATION OF EXTRINSIC (TISSUE-TYPE) PLASMINOGEN ACTIVATOR , 1981, The Lancet.

[50]  D. Collen,et al.  Purification and characterization of the plasminogen activator secreted by human melanoma cells in culture. , 1981, The Journal of biological chemistry.

[51]  M S Golden,et al.  Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. , 1980, The New England journal of medicine.

[52]  E. Hoal,et al.  Molecular species of plasminogen activators secreted by normal and neoplastic human cells. , 1980, Cancer research.

[53]  D. Rijken,et al.  Purification and partial characterization of plasminogen activator from human uterine tissue. , 1979, Biochimica et biophysica acta.

[54]  B. Wiman,et al.  On the biological significance of the specific interaction between fibrin, plasminogen and antiplasmin. , 1978, Biochimica et biophysica acta.

[55]  G. Claeson,et al.  Designing of peptide substrates. Different approaches exemplified by new chromogenic substrates for kallikreins and urokinase. , 1978, Haemostasis.

[56]  G. Barlow.  Urinary and kidney cell plasminogen activator (urokinase). , 1976, Methods in enzymology.

[57]  M. Bernik,et al.  Plasminogen activator and proactivator (urokinase precursor) in lung cultures. , 1976, Journal of the American Medical Women's Association.

[58]  A. Amery,et al.  Single-blind randomised multicentre trial comparing heparin and streptokinase treatment in recent myocardial infarction. , 1969, Acta medica Scandinavica. Supplementum.

[59]  W. White,et al.  The isolation and characterization of plasminogen activators (urokinase) from human urine. , 1966, Biochemistry.

[60]  A. Amery,et al.  Thrombolytic therapy with streptokinase using a standard dosage. , 1966, Thrombosis et diathesis haemorrhagica. Supplementum.

[61]  A. Fletcher,et al.  THE DEVELOPMENT OF UROKINASE AS A THROMBOLYTIC AGENT. MAINTENANCE OF A SUSTAINED THROMBOLYTIC STATE IN MAN BY ITS INTRAVENOUS INFUSION. , 1965, The Journal of laboratory and clinical medicine.

[62]  A. Amery,et al.  Feasibility of Adequate Thrombolytic Therapy with Streptokinase in Peripheral Arterial Occlusions: I. Clinical and Arteriographic Results , 1963, British medical journal.

[63]  A. Amery,et al.  The Streptokinase Reactivity Test. I. Standardization , 1963, Thrombosis and Haemostasis.

[64]  A. Amery,et al.  The feasibility of adequate thrombolytic therapy with streptokinase in peripheral arterial occlusions , 1962 .

[65]  A. Johnson,et al.  The lysis of artificially induced intravascular clots in man by intravenous infusions of streptokinase. , 1959, The Journal of clinical investigation.

[66]  S. Roszkowski,et al.  [Tissue fibrinolysis]. , 1959, Polskie Archiwum Medycyny Wewnetrznej.

[67]  B. Petrov.  Transfusion of cadaver blood. , 1959, Surgery.

[68]  A. Fletcher,et al.  The clearance of heterologous protein from the circulation of normal and immunized man. , 1958, The Journal of clinical investigation.

[69]  T. Astrup.  Fibrinolysis in the organism. , 1956, Blood.

[70]  M. Lassen.  Heat denaturation of plasminogen in the fibrin plate method. , 1953, Acta physiologica Scandinavica.

[71]  C. Grossi,et al.  In vivo studies of human plasmin; intravenous injection in dogs and rabbits. , 1953, Journal of applied physiology.

[72]  W. Tillett,et al.  THE LYSIS IN RABBITS OF INTRAVASCULAR BLOOD CLOTS BY THE STREPTOCOCCAL FIBRINOLYTIC SYSTEM (STREPTOKINASE) , 1952, The Journal of experimental medicine.

[73]  W. Tillett,et al.  THE EFFECT IN PATIENTS OF STREPTOCOCCAL FIBRINOLYSIN (STREPTOKINASE) AND STREPTOCOCCAL DESOXYRIBONUCLEASE ON FIBRINOUS, PURULENT, AND SANGUINOUS PLEURAL EXUDATIONS. , 1949, The Journal of clinical investigation.

[74]  R. G. Macfarlane,et al.  Fibrinolysis; its mechanism and significance. , 1948, Blood.

[75]  L. R. Christensen.  PROTAMINE PURIFICATION OF STREPTOKINASE AND EFFECT OF pH AND TEMPERATURE ON REVERSIBLE INACTIVATION , 1947, The Journal of general physiology.

[76]  L. R. Christensen.  STREPTOCOCCAL FIBRINOLYSIS: A PROTEOLYTIC REACTION DUE TO A SERUM ENZYME ACTIVATED BY STREPTOCOCCAL FIBRINOLYSIN , 1945, The Journal of general physiology.

[77]  C. S. Davidson,et al.  THE COAGULATION DEFECT IN HEMOPHILIA: A COMPARISON OF THE PROTEOLYTIC ACTIVITY OF CHLOROFORM PREPARATIONS OF HEMOPHILIC AND NORMAL HUMAN PLASMA. , 1943, The Journal of clinical investigation.

[78]  H. Milstone.  A Factor in Normal Human Blood which Participates in Streptococcal Fibrinolysis , 1941, The Journal of Immunology.

[79]  W. Tillett,et al.  THE FIBRINOLYTIC ACTIVITY OF HEMOLYTIC STREPTOCOCCI , 1933, The Journal of experimental medicine.

[80]  Katherine A. Hajjart.  The Endothelial Cell Tissue Plasminogen Activator Receptor , 2022 .